Eczema now affects over 200 million people worldwide, making it the most common inflammatory skin disease. Prevalence has increased sharply, rising by 60% among children in the US alone over the past 30 years.
Key Takeaways
- Genetic mutations in filaggrin gene cause barrier dysfunction in 20-30% severe eczema
- Severe eczema increases risk of asthma by 2-3 fold, atopic march
- Approximately 31.6 million people in the United States, or 10.1% of the population, are affected by eczema, with higher rates among children under 18 at 13.1%
- Atopic dermatitis, the most common eczema type, features intense itching as primary symptom affecting 90% of patients
- Topical calcineurin inhibitors effective in 80% moderate-severe cases
Eczema affects millions worldwide, making it a common chronic condition with significant quality of life impacts.
Related reading
01 · Category
Causes and Risk Factors26 stats
01
Genetic mutations in filaggrin gene cause barrier dysfunction in 20-30% severe eczema
02
Family history of atopy increases risk 3-fold; if both parents affected, 60-80% child risk
03
Early-life exposure to allergens like dust mites elevates risk by 1.5-2 times
04
Low vitamin D levels (<20 ng/mL) associate with 1.8x higher eczema odds in infants
05
Breastfeeding for >3 months reduces eczema risk by 27% in high-risk infants
06
Staphylococcus aureus colonization on skin in 90% eczema patients vs 5% healthy
07
Urban living increases eczema risk 1.4-fold due to pollution exposure
08
Maternal smoking during pregnancy raises child eczema risk by 30-50%
09
Filaggrin loss-of-function mutations in 27% European eczema patients
10
Probiotic use in pregnancy reduces eczema incidence by 20% in meta-analysis
11
High maternal intake of omega-3 fatty acids lowers child eczema risk 17%
12
Daycare attendance before 1 year increases eczema risk 1.6x via infections
13
Obesity BMI>30 associates with 1.5x adult eczema prevalence
14
Hard water (>100 mg/L CaCO3) exposure raises risk 87% in infants
15
Cesarean delivery increases eczema risk 1.3-fold vs vaginal birth, microbiome effect
16
Early antibiotic use (<6 months) triples eczema development risk
17
Pets in home during infancy protect against eczema, OR 0.7, hygiene hypothesis
18
Stressful life events double eczema flare risk via cortisol dysregulation
19
Soy formula feeding in infancy increases eczema 1.5x vs cow's milk
20
Climate: cold dry winter air exacerbates eczema 2x more than humid tropics
21
Immune dysregulation Th2 skewing in 80% atopic eczema, IL-4/13 elevated
22
Contact allergens like nickel sensitize 15-20% hand eczema cases
23
Food allergens trigger 30% infantile eczema, cow's milk/egg common
24
Sleep deprivation from pruritus creates vicious cycle, worsening barrier in 70%
25
Textile irritants like wool provoke flares in 25% sensitive patients
26
Vitamin D deficiency OR 2.1 for eczema in meta-analysis of 21 studies
Interpretation
Causes and Risk Factors Interpretation
If your family tree is riddled with eczema, your city's air is thick, and your diet lacks vitamin D, your skin might rebel so spectacularly that scratching the itch becomes a sleepless, self-perpetuating science project of barrier dysfunction, bacterial colonization, and immune dysregulation.
02 · Category
Complications and Prognosis30 stats
01
Severe eczema increases risk of asthma by 2-3 fold, atopic march
02
Bacterial skin infections occur in 90% of severe eczema flares due to barrier breach
03
Eczema herpeticum, disseminated HSV, mortality 1-9% untreated
04
Chronic sleep loss from pruritus raises obesity risk 60% in children
05
Allergic contact dermatitis overlays in 40% chronic hand eczema cases
06
Severe eczema associates with ADHD diagnosis 1.7x higher odds
07
Kaposi's varicelliform eruption (eczema vaccinatum) post-vaccination rare, 0.01%
08
Growth retardation in 20% severe untreated pediatric eczema
09
Depression prevalence 25% in adult moderate-severe eczema vs 7% general
10
Osteoporosis risk elevated 1.5x from chronic topical steroid use
11
Food allergy develops in 25% eczema infants, egg/milk common
12
Eczema increases anaphylaxis risk 6-fold in sensitized patients
13
Scarring alopecia from scalp eczema in 5% chronic cases
14
Cardiovascular disease risk 1.3x higher in severe eczema adults
15
Antibiotic resistance S. aureus MRSA in 20% colonized eczema patients
16
Anxiety disorders 2x prevalence in pediatric eczema cohort studies
17
Visual impairment from chronic eyelid eczema 10% severe cases
18
Rheumatoid arthritis comorbidity OR 1.7 in atopic eczema
19
30% of childhood eczema persists into adulthood, worse prognosis if early onset
20
Healthcare costs for eczema $29 billion annually in US, mostly severe cases
21
School absenteeism 15% higher in children with eczema vs controls
22
Chronic urticaria coexists in 18% adult eczema patients
23
Lymphoma risk slightly elevated RR 1.4 in severe long-term eczema
24
Pneumonia hospitalization 1.6x in severe eczema children, infection prone
25
Quality of life DLQI scores average 10.5 in moderate eczema, comparable psoriasis
26
Work productivity loss 25% in adult hand eczema sufferers
27
Otitis media recurrent 2x frequency in atopic eczema toddlers
28
Cataract formation risk 1.9x from topical/ systemic steroids long-term
29
Social stigma leads to bullying in 27% school-age eczema children
30
Migraine headache prevalence 1.5x in adult eczema population
Interpretation
Complications and Prognosis Interpretation
Eczema is the body's mischievous architect, designing not just itchy skin but a blueprint for a bewildering cascade of systemic disasters that range from asthma and depression to infections and even heart disease, proving that a superficial irritation is anything but.
03 · Category
Prevalence and Epidemiology30 stats
01
Approximately 31.6 million people in the United States, or 10.1% of the population, are affected by eczema, with higher rates among children under 18 at 13.1%
02
Globally, eczema affects over 200 million people, making it the most common inflammatory skin disease worldwide
03
In the UK, 1 in 5 children and 1 in 10 adults develop eczema, with prevalence rates peaking at 20% in children aged 1-5 years
04
Eczema prevalence in the US has increased by 60% over the past 30 years, from 6.5% in 1988 to 10.7% in 2018 among children
05
Among African American children in the US, eczema prevalence is 19.3%, compared to 12.1% in white children, showing racial disparities
06
In Australia, 30% of children under 6 years old have eczema, one of the highest rates globally
07
Eczema affects 15-20% of children worldwide, with 60% developing symptoms in the first year of life
08
In urban areas of developing countries like India, eczema prevalence in children is 12.5%, higher than rural 8.2%
09
Lifetime prevalence of eczema in Europe ranges from 15-30% in children and 2-10% in adults
10
In Japan, hand eczema affects 10% of the general population, with occupational cases comprising 90% of adult consultations
11
Eczema prevalence among US adults is 7.2%, with women affected at 8.2% versus 6.2% in men
12
In China, childhood eczema prevalence has risen to 9.2% from 4.1% in the 1990s due to urbanization
13
Severe eczema impacts 1.3% of US children, leading to 1,500 emergency visits per 100,000 cases annually
14
In Scandinavia, eczema prevalence in children is 25%, linked to cold climates and hygiene practices
15
Global burden of eczema measured in DALYs is 1.3 million, ranking it among top 20 skin diseases
16
In low-income countries, eczema prevalence is 7.9% in children, lower than high-income 18.1%
17
US military personnel show 12% eczema prevalence, higher due to stress and exposures
18
In South Korea, 23.8% of elementary school children have eczema, per ISAAC study
19
Eczema remission occurs in 60-70% of children by adolescence, but 30% persist into adulthood
20
In Brazil, urban eczema prevalence in children is 18.6%, influenced by pollution
21
African children have 20.4% eczema prevalence, highest among ethnic groups globally
22
In Canada, 10.5% of adults report doctor-diagnosed eczema
23
Singapore reports 22% childhood eczema rate, among Asia's highest
24
Eczema affects 16.5% of US children with food allergies, comorbidity rate
25
In Germany, adult eczema prevalence is 4.5%, with 2 million cases annually
26
Global pediatric eczema incidence is 15%, with 40% family history
27
In New Zealand, Maori children have 23% eczema vs 11% in Europeans
28
US eczema healthcare visits total 12 million annually, mostly pediatric
29
In Sweden, 20% of 2-year-olds have eczema, decreasing to 7% by age 12
30
Worldwide, eczema causes 68 million prescriptions yearly in high-income countries
Interpretation
Prevalence and Epidemiology Interpretation
So while eczema may be considered a trivial 'skin' condition by some, its sprawling global empire of itchy citizens—from Australia's toddler battalions to America's military ranks—proves it's a surprisingly democratic, uncomfortably tenacious, and decidedly un-funny ruler of the largest inflamed nation on Earth.
More related reading
04 · Category
Symptoms and Clinical Features29 stats
01
Atopic dermatitis, the most common eczema type, features intense itching as primary symptom affecting 90% of patients
02
Red, inflamed, scaly patches on skin, often on face, elbows, knees, appear in 80% of childhood eczema cases
03
Dry, cracked skin that bleeds occurs in severe eczema, with oozing and crusting in 50% acute flares
04
Intense nocturnal pruritus disrupts sleep in 60% of children with moderate-severe eczema
05
Flexural eczema in adults typically affects antecubital fossae in 70% of cases
06
Lichenification from chronic scratching seen in 40% long-term patients, thickening skin
07
Eyelid eczema causes swelling and scaling in 25% of facial involvement cases
08
Hand eczema presents with vesicles, fissures, hyperkeratosis in 80% occupational cases
09
Nummular eczema shows coin-shaped lesions 1-10cm diameter, pruritic in 90%
10
Asteatotic eczema in elderly features fish-scale cracking on shins, 30% over 65
11
Perioral dermatitis mimics eczema with papules around mouth in 15% misdiagnosed
12
Excoriations from scratching lead to secondary infection signs in 70% flares
13
Pruritus intensity scores average 7/10 on VAS in moderate eczema
14
Erythema grading: mild (pink), moderate (red), severe (deep red/purple) in SCORAD system
15
Sleep disturbance measured by SCORAD-A component affects 85% severe cases
16
Facial eczema in infants covers cheeks in 95%, sparing diaper area
17
Dyshidrotic eczema on palms/soles shows tapioca-like vesicles in 60%
18
Post-inflammatory hyperpigmentation follows flares in 50% darker skin types
19
Nipple eczema in breastfeeding women causes fissuring, pain in 10-20%
20
Ear eczema leads to otitis externa in 30% untreated cases
21
Scalp eczema presents with greasy scales, itching in 40% seborrheic overlap
22
Foot eczema fissures cause pain on walking in 25% chronic cases
23
Photosensitivity worsens eczema in 20% patients with polymorphic light eruption
24
Xerosis precedes flares in 90% atopic eczema patients
25
Anhidrosis in affected areas reduces sweating, exacerbating heat in 15%
26
Oral allergy syndrome overlaps with lip eczema in 35% food-allergic patients
27
Ichthyosis vulgaris coexists with eczema in 50% cases, rough dry skin
28
Acute eczema shows weeping vesicles, subacute plaques, chronic lichenified
29
Eczema herpeticum presents clustered vesicles, fever in 5% severe atopic
Interpretation
Symptoms and Clinical Features Interpretation
Atopic dermatitis is not merely a cosmetic nuisance but a tormenting, multifaceted skin rebellion where relentless itching commands an army of symptoms—from nocturnal misery and painful cracks to coin-shaped lesions and weeping vesicles—that dominate the lives of patients, turning every day into a battle against their own skin.
05 · Category
Treatments and Management29 stats
01
Topical calcineurin inhibitors effective in 80% moderate-severe cases
02
Topical corticosteroids tiered: mild 1% hydrocortisone for face, potent clobetasol for body
03
Wet wrap therapy with emollients/corticosteroids improves SCORAD by 70% in 7 days
04
Dupilumab, IL-4/13 inhibitor, clears 38% severe eczema patients at 16 weeks
05
Daily emollient use from birth prevents eczema in high-risk infants by 50%, BEEP trial
06
Crisaborole PDE4 inhibitor reduces symptoms 32% vs 25% vehicle at 4 weeks
07
Narrowband UVB phototherapy achieves 75% improvement in 60% chronic cases
08
Oral cyclosporine induces remission in 60% severe refractory eczema short-term
09
Bleach baths (0.5 cup/8L water) reduce S. aureus 50%, flares by 1/3
10
Abrocitinib JAK1 inhibitor clears EASI-75 in 44% vs 8% placebo at 12 weeks
11
Upadacitinib JAK inhibitor achieves 80% EASI-75 in phase 3 trials
12
Tralokinumab IL-13 mAb improves IGA 0/1 in 16% vs 7% placebo at 16 weeks
13
Oral methotrexate 10-15mg/week effective in 40% refractory pediatric cases
14
Probiotics Lactobacillus rhamnosus reduce eczema risk 50% in high-risk infants
15
Antihistamines like hydroxyzine aid sleep but minimal itch relief, 20% adjunct benefit
16
Allergen immunotherapy reduces eczema flares 40% in pollen-sensitized
17
Calcineurin inhibitors tacrolimus 0.1% ointment clears 70% facial eczema
18
Wet dressings with diluted vinegar soothe acute flares, 60% patient satisfaction
19
Oral steroids prednisone short burst for severe flares, relapse 50% within week
20
House dust mite avoidance measures reduce symptoms 30% in sensitized children
21
PDE4 inhibitor roflumilast cream 0.15% EASI-50 42% vs 20% vehicle
22
Baricitinib JAK inhibitor IGA 0/1 16% at week 16 phase 3
23
Educational programs improve adherence, reduce flares 35%
24
Dilute sodium hypochlorite baths decrease infection rates 50%
25
Azathioprine 2-3mg/kg/day remission 50-70% severe cases, monitor TPMT
26
Psychological interventions CBT reduce itch 30% via stress management
27
Manuka honey dressings heal infected eczema 80% faster than standard
28
Eczema herpeticum requires IV acyclovir, mortality <1% with prompt tx
29
Sleep hygiene plus melatonin improves quality 40% in pediatric eczema
Interpretation
Treatments and Management Interpretation
The eczema treatment landscape is a bewildering but hopeful arsenal where the best strategy is a layered defense—starting with gentle daily moisturizers for prevention, escalating through targeted topicals and immunosuppressants for flares, and sometimes reaching for game-changing biologics that are nothing short of modern medical alchemy.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Eczema Statistics. Gitnux. https://gitnux.org/eczema-statistics
MLA
Henrik Dahl. "Eczema Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/eczema-statistics.
Chicago
Henrik Dahl. 2026. "Eczema Statistics." Gitnux. https://gitnux.org/eczema-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level